<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dtd-version="1.3" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2025.1616132</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The global burden of osteoarthritis hand: lessons from the Global Burden of Disease Study 1990&#x02013;2021</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Wei</surname> <given-names>Jiyong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/880639"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Su</surname> <given-names>Zhongyi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Pan</surname> <given-names>Songmu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zou</surname> <given-names>Zhuan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing Gui" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing-gui/">Writing &#x02013; review &#x00026; editing Gui</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liao</surname> <given-names>Gui</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing Gua" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing-gua/">Writing &#x02013; review &#x00026; editing Gua</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Guangxiong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Huijiang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1740677"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing Guip" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing-guip/">Writing &#x02013; review &#x00026; editing Guip</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Lan</surname> <given-names>Guipeng</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Gu</surname> <given-names>Ronghe</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lan</surname> <given-names>Yanni</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2513515"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Orthopedic Surgery, The First People's Hospital of Nanning, The Fifth Affiliated Hospital of Guangxi Medical University</institution>, <city>Nanning</city>, <state>Guangxi</state>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region &amp; Guangxi Academy of Medical Sciences</institution>, <city>Nanning</city>, <state>Guangxi</state>, <country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Bone Surgery, The Eight People's Hospital of Nanning</institution>, <city>Nanning</city>, <state>Guangxi</state>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x0002A;</label>Correspondence: Yanni Lan, <email xlink:href="mailto:237911623@qq.com">237911623@qq.com</email></corresp>
<fn fn-type="equal" id="fn001"><label>&#x02020;</label><p>These authors have contributed equally to this work and share first authorship</p></fn></author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-07-31">
<day>31</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="corrected" iso-8601-date="2026-08-21">
<day>21</day>
<month>08</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1616132</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2025 Wei, Su, Pan, Zou, Liao, Li, Liu, Lan, Gu and Lan.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Wei, Su, Pan, Zou, Liao, Li, Liu, Lan, Gu and Lan</copyright-holder>
<license>
<ali:license_ref start_date="2025-07-31">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Hand osteoarthritis (HOA), a disabling musculoskeletal disorder, poses a significant global burden but remains understudied relative to other osteoarthritis (OA) subtypes. Using data from the Global Burden of Disease (GBD) Study 1990&#x02013;2021, this analysis characterizes HOA epidemiology, temporal trends, and future projections.</p></sec>
<sec>
<title>Methods</title>
<p>GBD 2021 data on HOA incidence, prevalence, and disability-adjusted life-years (DALYs) were stratified by sex, age, Socio-demographic Index (SDI) regions, GBD regions, and countries. Temporal trends (1990&#x02013;2021) were assessed via estimated annual percentage changes (EAPCs), with future projections (2022&#x02013;2046) generated using an age-period-cohort (APC) model.</p></sec>
<sec>
<title>Results</title>
<p>In 2021, HOA accounted for 10.37 million incidence cases, 194.28 million prevalence cases, and 6.17 million DALYs. Female burdens were 1.8&#x02013;2.0 times higher than males in absolute terms and 1.75&#x02013;1.78 times higher in age-standardized rates (ASRs). Incidence cases peaked in advanced ages before declining, while prevalence/DALYs rose monotonically with age. Middle SDI regions had the highest absolute burdens, whereas high SDI regions showed the highest ASRs. Central Asia emerged as a burden hotspot, while minimal health system regions and sub-Saharan Africa had the lowest rates. From 1990 to 2021, global incidences increased 142%. Low/middle-income regions (such as South Asia) saw significant increases, contrasting with declines in high-income areas (such as Western Europe). APC projections indicate continued growth through 2046, with male/female incidences rising 69.6%/51.6% and ASRs increasing for both sexes.</p></sec>
<sec>
<title>Conclusion</title>
<p>HOA represents a growing global challenge with pronounced sex/age/regional disparities. Targeted interventions in high-burden regions, aging populations, and risk factor management are critical to mitigate projected burden increases.</p></sec></abstract>
<kwd-group>
<kwd>osteoarthritis</kwd>
<kwd>hand</kwd>
<kwd>global</kwd>
<kwd>disease burden</kwd>
<kwd>GBD</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
  <funding-source id="sp1">
    <institution-wrap>
      <institution>Natural Science Foundation of Guangxi Zhuang Autonomous Region</institution>
      <institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100012547</institution-id>
    </institution-wrap>
  </funding-source>
  <award-id rid="sp1">2024GXNSFBA999270</award-id>
</award-group>
<award-group id="gs2">
  <funding-source id="sp2">
    <institution-wrap>
      <institution>Guangxi Zhuang Autonomous Region Health Department</institution>
      <institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100003454</institution-id>
    </institution-wrap>
  </funding-source>
  <award-id rid="sp2">GXZYA20220182</award-id>
</award-group>
  <funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. The work was financially supported by Natural Science Foundation of Guangxi Zhuang Autonomous Region, China (No. 2024GXNSFBA999270) and Self-Funded Research Project by Administration of Traditional Chinese Medicine of Guangxi Zhuang Autonomous Region, China (No. GXZYA20220182).</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="2"/>
<ref-count count="48"/>
<page-count count="0"/>
<word-count count="6570"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Geriatric Medicine</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>1 Introduction</title>
<p>Osteoarthritis (OA) is a leading contributor to chronic pain and disability globally, particularly in the context of aging populations and lifestyle transitions (<xref ref-type="bibr" rid="B1">1</xref>). Among its subtypes, hand osteoarthritis (HOA) poses a substantial yet underrecognized burden due to its impact on manual function, productivity, and quality of life. Despite its clinical significance, HOA has historically received less attention than knee or hip OA, even as emerging data from the Global Burden of Disease (GBD) Study 2021 reveal its escalating incidence, prevalence, and disability toll (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>GBD 2021 estimates suggest that OA affected 595 million individuals worldwide in 2020, with HOA accounting for a considerable share (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B3">3</xref>). By 2050, HOA cases are projected to rise by 48.6%, largely driven by population aging, increasing obesity, and occupational exposures (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>). The age-standardized disability-adjusted life-years (DALYs) rate for OA increased by 9.5% between 1990 and 2020, underscoring its growing global impact (<xref ref-type="bibr" rid="B1">1</xref>). While high sociodemographic index (SDI) countries report the highest prevalence, low- and middle-SDI regions are experiencing the most rapid increases in incidence&#x02014;reflecting healthcare disparities, under diagnosis, and delayed access to treatment (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>). For instance, Asia-Pacific countries report disproportionately high HOA burdens, potentially due to genetic predispositions, manual labor intensity, and diagnostic delays (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Elevated body mass index remains the dominant modifiable risk factor, implicated in 20.4% of global OA cases, including HOA (<xref ref-type="bibr" rid="B1">1</xref>). Yet, occupational stressors&#x02014;such as repetitive manual tasks in agriculture or manufacturing&#x02014;and joint trauma are underexplored contributors, particularly in younger working populations (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>). A worrying trend is the earlier onset of HOA, with individuals under 55 increasingly affected, leading to prolonged disability, joint surgeries, and estimated annual productivity losses exceeding US$106.8 billion in some economies (<xref ref-type="bibr" rid="B8">8</xref>). These challenges are compounded by the lack of disease-modifying treatments, with most interventions aimed solely at symptom relief (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>The GBD framework has enabled a systematic assessment of HOA&#x00027;s global epidemiology and its regional disparities. Countries such as Denmark demonstrate success in reducing OA rates through proactive public health measures, while low-SDI settings continue to face rising incidence amidst limited resources (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>). Meanwhile, gender disparities persist, with women experiencing 20%&#x02212;30% higher HOA prevalence&#x02014;largely due to hormonal influences and disproportionate involvement in caregiving and manual occupations (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Aging and population growth remain key drivers, accounting for over 60% of the rising HOA burden in low-SDI settings (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Nonetheless, important knowledge gaps remain. The current GBD framework does not incorporate occupational hazards or joint trauma as formal risk factors, limiting the identification of actionable prevention targets (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Furthermore, economic data on HOA burden are scarce, particularly in resource-limited settings where out-of-pocket costs contribute to health inequities (<xref ref-type="bibr" rid="B9">9</xref>). Integrating socioeconomic and occupational determinants&#x02014;such as informal labor, ergonomic exposures, and income inequality&#x02014;into future GBD iterations will be essential to guide effective interventions.</p>
<p>In light of these persisting gaps, the present study provides the first comprehensive assessment of the global, regional, and national burden of HOA from 1990 to 2021, with forecasts extending to 2046. Leveraging data from the GBD 2021 study and employing age-period-cohort (APC) modeling techniques, we delineate temporal trends, sex- and age-specific patterns, and geospatial heterogeneity in HOA burden. This work identifies emerging hotspots and divergent trajectories across sociodemographic contexts, offering critical evidence to guide equity-focused musculoskeletal health strategies and inform policy prioritization in the post-2020 global health landscape.</p></sec>
<sec sec-type="methods" id="s2">
<title>2 Methods</title>
<sec>
<title>2.1 Data sources</title>
<p>The data for this study were primarily sourced from the GBD 2021 Study (<xref ref-type="bibr" rid="B9">9</xref>). The GBD study is a comprehensive, systematic scientific effort to quantify the comparative health loss from a wide array of diseases, injuries, and risk factors at global, regional, and national levels. It compiles data from a vast number of sources, including population-based surveys, vital registration systems, disease registries, and published literature, providing a rich and globally representative dataset for our analysis of HOA.</p></sec>
<sec>
<title>2.2 Data collection</title>
<p>The data collection process within the GBD study is highly standardized and rigorous. Trained researchers and data collectors from around the world contribute to gathering relevant health information. For HOA-specific data, multiple data collection methods were employed. In population-based surveys, individuals were interviewed about their symptoms, medical history, and any diagnosed joint conditions. Medical records from hospitals, clinics, and primary care providers were also systematically abstracted to identify cases of HOA. Additionally, disease registries, where available, provided valuable longitudinal data on the incidence and prevalence of HOA. The use of multiple data collection methods helps to ensure the comprehensiveness and accuracy of the HOA-related data included in the GBD dataset (<xref ref-type="bibr" rid="B10">10</xref>).</p></sec>
<sec>
<title>2.3 Statistical analysis</title>
<p>First, the description of the disease burden was carried out. In 2021, the number of incidence, prevalence, and DALYs of HOA, along with their corresponding age-standardized rates (ASRs), were reported globally and stratified by different sub-types. These sub-types included sex, age groups, SDI regions, GBD regions, and individual countries.</p>
<p>Second, to explore the temporal trend of the disease burden, data from 1990 to 2021 were analyzed both globally and by sub-types. To quantify temporal trends in the ASRs of incidence, prevalence, and DALYs, we estimated the Estimated Annual Percentage Change (EAPC) using a log-linear regression model. ASRs were calculated using the direct standardization method by applying age-specific rates to the GBD 2021 global standard population, which includes 5-year age groups from &#x0003C;1 year to &#x02265;95 years (<xref ref-type="bibr" rid="B1">1</xref>). This approach enables comparison across populations by adjusting for differences in age structure. Specifically, we fitted the natural logarithm of the ASR against calendar year as follows:</p>
<disp-formula id="E1"><mml:math id="M1"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>ASR</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mtext>&#x000A0;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#x000A0;&#x003B1;&#x000A0;</mml:mtext><mml:mo>&#x0002B;</mml:mo><mml:mtext>&#x000A0;&#x003B2;&#x000A0;</mml:mtext><mml:mo>&#x000D7;</mml:mo><mml:mtext>&#x000A0;year&#x000A0;</mml:mtext><mml:mo>&#x0002B;</mml:mo><mml:mtext>&#x000A0;&#x003B5;</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
<p>where &#x003B2; represents the annual rate of change. The EAPC and its 95% confidence interval (CI) were then calculated as:</p>
<disp-formula id="E2"><mml:math id="M2"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mtext>EAPC&#x000A0;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#x000A0;</mml:mtext><mml:mn>100</mml:mn><mml:mtext>&#x000A0;</mml:mtext><mml:mo>&#x000D7;</mml:mo><mml:mtext>&#x000A0;</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>exp&#x000A0;</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>&#x003B2;</mml:mtext></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mtext>&#x000A0;</mml:mtext><mml:mo>-</mml:mo><mml:mtext>&#x000A0;</mml:mtext><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
<p>A statistically significant increasing trend was defined as an EAPC &#x0003E; 0 with a 95% CI entirely above zero; a decreasing trend as an EAPC &#x0003C;0 with a 95% CI entirely below zero; and a stable trend when the 95% CI included zero. This method allowed us to robustly assess the temporal dynamics of HOA burden across populations.</p>
<p>Based on the obtained EAPC values for age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDAR), we conducted a hierarchical agglomerative cluster analysis to identify regions with similar temporal patterns of HOA burden. Each of the 50 GBD regions was represented by a three-dimensional vector (EAPC of incidence, prevalence, and DALYs). Clustering was performed using Ward&#x00027;s minimum variance method as the linkage criterion and Euclidean distance as the dissimilarity metric. The optimal number of clusters was selected by visually inspecting the dendrogram structure to ensure both within-cluster homogeneity and between-cluster separation. This approach enabled the identification of epidemiologically similar regions and provided insight into global trend heterogeneity. All geographic classifications, including SDI strata and GBD regions, were based on the GBD 2021 framework to ensure standardization and comparability.</p>
<p>Finally, to predict the future disease burden from 2020 to 2044, the APC model under the maximum likelihood framework was applied. To forecast the future burden of HOA, we employed an APC model under a maximum likelihood framework. The APC model disentangles the effects of age, calendar period, and birth cohort on disease rates, capturing demographic and generational shifts over time. It assumes a relatively stable population structure and risk factor distribution, making it suitable for chronic disease projections. Compared with time-series models, the APC approach offers superior epidemiological interpretability and has been widely validated in disease burden forecasting, including in GBD studies (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Its application has also shown superior performance over conventional time-series models in chronic disease projections (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>All analyses, including data management, statistical modeling, and figure generation, were conducted using R software (version 4.0.2; R Foundation for Statistical Computing, Vienna, Austria). Standard errors for estimates were derived via likelihood-based inference. Statistical significance was defined as a two-tailed <italic>P</italic> value &#x0003C; 0.05.</p></sec></sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec>
<title>3.1 The disease burden attributable to HOA in 2021</title>
<p>In 2021, the number of HOA-related incidence cases amounted to 10,367,241 [95% uncertainty intervals (UI): 7,686,291&#x02013;13,251,881]. The corresponding ASIR was 119.09 (95% UI: 88.73&#x02013;151.13) per 100,000 population. The number of HOA-related prevalence cases reached 194,284,754 (95% UI: 146,479,865&#x02013;248,177,668) in 2021, with a corresponding ASPR of 2,237.78 (95% UI: 1,693.67&#x02013;2,851.21) per 100,000 population. The number of DALYs attributable to HOA was 6,167,308 (95% UI: 2,803,411&#x02013;12,737,380), and the corresponding ASDAR was 70.94 (95% UI: 32.23&#x02013;146.27) per 100,000 population (<xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>In 2021, the number of incidence, prevalence, and DALYs cases in females was 1.83, 2.00, and 1.97 times higher than that in males, respectively. The corresponding ASRs in females were 1.75, 1.78, and 1.76 times those in males (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>The distribution of incidence, prevalence, and DALYs across age groups in 2021 is presented in <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>. The number of incidence, prevalence, and DALYs cases initially increased with age, reaching a peak and then declining. The ASPR and ASDAR continuously increased with age. However, the ASIR first increased with age, then decreased, and finally increased again (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>At the SDI region level, the middle SDI region had the largest number of incidence cases, which was 3,413,861 (95% UI: 2,523,021&#x02013;4,379,118), prevalence cases of 57,871,145 (95% UI: 43,457,254&#x02013;73,924,364), and DALYs cases of 1,843,413 (95% UI: 837,552&#x02013;3,833,754). The highest ASRs were observed in the high SDI region, with an ASIR of 147.54 (95% UI: 109.86&#x02013;188.12), an ASPR of 2,780.32 (95% UI: 2,098.02&#x02013;3,562.49), and an ASDAR of 88.47 (95% UI: 40.04&#x02013;182.48; <xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>Across the 50 GBD regions, Asia ranked the top one in number of incidence cases (5,758,148), followed by Advanced Health System (3,395,089) and Basic Health System (4,275,470). Advanced Health System also ranked the top one for number of prevalence cases (78,047,872), followed by Asia (100,372,746) and Europe (42,559,011). For DALYs cases, Asia led (3,197,459), followed by Advanced Health System (2,465,289) and America (1,202,432). However, Oceania ranked the bottom one for incidence (8,831), prevalence (126,572), and DALYs (4,061). For ASRs, Central Asia had the highest ASIR (194.58/100,000), while Minimal Health System ranked the lowest (76.71/100,000). The highest ASPR was in Central Asia (3,903.67/100,000), and the lowest in Minimal Health System (1,387.27/100,000). Central Asia also led in ASDAR (124.56/100,000), with Minimal Health System again at the bottom (43.77/100,000). Regions consistently ranking low included Commonwealth Low Income, Western Africa, and Western Sub-Saharan Africa (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>The disease burden of HOA varied considerably across the world, with the highest ASIR observed in Mongolia (217.97/100,000), followed by Kazakhstan (221.12/100,000) and Estonia (204/100,000). The lowest ASIR was in Burkina Faso (57.2/100,000), followed by South Sudan (61.98/100,000) and Niger (62.09/100,000). For ASPR, the highest rates were in Mongolia (4,430.54/100,000), Latvia (4,083.12/100,000), and Lithuania (4,032.3/100,000), while the lowest were in Burkina Faso (995.97/100,000), Madagascar (1,102.49/100,000), and Burundi (1,244.52/100,000). The highest ASDAR was in Mongolia (141.61/100,000), followed by Kazakhstan (145.11/100,000) and Turkmenistan (123.93/100,000), with the lowest in Burkina Faso (31.69/100,000), South Sudan (33.57/100,000), and Niger (34.31/100,000). In terms of absolute numbers, China had the highest number of incidence cases (1,960,255), followed by India (1,563,214) and the United States of America (803,664). The United States of America also led in number of prevalence (17,926,585) and DALYs (558,646) cases, followed by China (34,420,008 prevalence; 1,103,886 DALYs) and India (25,505,889 prevalence; 801,114 DALYs). The lowest numbers were in Tokelau (two incidence, 35 prevalence, one DALY), followed by Niue (three incidence, 55 prevalence, two DALY) and Nauru (10 incidence, 144 prevalence, five DALY; <xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). Estimates from microstate territories such as Tokelau and Niue should be interpreted with caution due to small population sizes and potential modeling uncertainty.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Age-standardized rates of osteoarthritis hand-related incidence, prevalence, and DALYs across countries and territories in 2021.</p></caption>
<alt-text>Three world maps display different age-standardized rates. Map A shows incidence rates ranging from 30 to 240, with distinct colors for each range. Map B depicts prevalence rates from 500 to 5000, also color-coded. Map C illustrates DALYs rates from 20 to 160, using various hues. Each map highlights regional differences globally.</alt-text>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-12-1616132-g0001.tif"/>
</fig></sec>
<sec>
<title>3.2 Temporal trend for HOA-related disease burden from 1990 to 2021</title>
<p>Globally, the number of HOA incidence cases increased from 4,282,225 (95% UI: 3,174,006&#x02013;5,467,719) in 1990 to 10,367,241 (95% UI: 7,686,291&#x02013;13,251,881) in 2021. The number of prevalence cases rose from 76,317,645 (95% UI: 57,748,915&#x02013;97,654,829) to 194,284,754 (95% UI: 146,479,865&#x02013;248,177,668), and the number of DALYs cases increased from 2,432,664 (95% UI: 1,103,100&#x02013;5,033,222) to 6,167,308 (95% UI: 2,803,411&#x02013;12,737,380). Regarding the corresponding ASRs, they all changed in the same upward direction. The ASIR increased from 100.57 (95% UI: 74.51&#x02013;128.13) to 119.09 (95% UI: 88.73&#x02013;151.13), the ASPR increased from 1,944.84 (95% UI: 1,476.85&#x02013;2,478.43) to 2,237.78 (95% UI: 1,693.67&#x02013;2,851.21), and the ASDAR increased from 61.67 (95% UI: 27.93&#x02013;127.04) to 70.94 (95% UI: 32.23&#x02013;146.27) per 100,000 population (<xref ref-type="fig" rid="F2">Figure 2</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Trends in the numbers and age-standardized rates of osteoarthritis hand-related incidence, prevalence, and DALYs globally from 1990 to 2021.</p></caption>
<alt-text>Three bar graphs showing trends from 1990 to 2020. Graph A (blue) depicts incidence numbers and age-standardized rates, both increasing. Graph B (red) shows prevalence numbers and rates, also rising. Graph C (yellow) represents DALYs numbers and rates, similarly increasing.</alt-text>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-12-1616132-g0002.tif"/>
</fig>
<p>The trends in males and females separately were consistent with those of the overall population (<xref ref-type="sec" rid="s11">Supplementary Figure S6</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>). Additionally, the trends were consistent across all age groups (<xref ref-type="sec" rid="s11">Supplementary Figure S7</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>). At the SDI region level, all SDI regions demonstrated the same trend as the overall population (<xref ref-type="sec" rid="s11">Supplementary Figure S8</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<p>Across GBD regions, the trend of the HOA-related disease burden showed variability. The results of cluster analysis are presented in <xref ref-type="fig" rid="F3">Figure 3</xref>. A significant increase in incidence, prevalence, and DALYs rate occurred in South Asia-WB, South Asia, Eastern Sub-Saharan Africa, Southeast Asia, Limited Health System, Asia, Commonwealth Middle Income, Basic Health System, Western Pacific Region, East Asia &#x00026; Pacific-WB, High-income Asia Pacific, South-East Asia Region, Eastern Africa, and East Asia. In contrast, a significant decrease was observed in Western Europe, Southern Latin America, Australasia, and Commonwealth High Income (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Results of cluster analysis based on the EAPC values of the osteoarthritis hand-related age-standardized rates for incidence, prevalence, and DALYs from 1990 to 2021.</p></caption>
<alt-text>Dendrogram showing the trends in various regions&#x00027; health systems. The legend indicates changes: minor increase (purple), stable or minor decrease (green), significant decrease (red), and significant increase (blue). Regions include Sub-Saharan Africa, North America, Europe, and Asia, among others.</alt-text>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-12-1616132-g0003.tif"/>
</fig>
<p>Across countries and territories, the changing trend also differed. From 1990 to 2021, Equatorial Guinea exhibited the most significant increase in ASIR [EAPC = 2.53, 95% confidence interval (CI): 2.35&#x02013;2.7], ASPR (EAPC = 2.77, 95% CI: 2.59&#x02013;2.95), and ASDAR (EAPC = 2.82, 95% CI: 2.63&#x02013;3.01). Israel showed the most significant decrease in ASIR (EAPC = &#x02212;1.33, 95% CI: &#x02212;1.90 to &#x02212;0.76), ASPR (EAPC = &#x02212;1.33, 95% CI: &#x02212;1.91 to &#x02212;0.76), and ASDAR (EAPC = &#x02212;1.36, 95% CI: &#x02212;1.94 to &#x02212;0.78; <xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="sec" rid="s11">Supplementary Tables S1</xref>&#x02013;<xref ref-type="sec" rid="s11">S3</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>The EAPC of osteoarthritis hand-related ASRs from 1990 to 2021.</p></caption>
<alt-text>Three world maps displaying EAPC (Estimated Annual Percentage Change) for age-standardized rates. Map A shows incidence rates, B shows prevalence rates, and C shows DALYs (Disability-Adjusted Life Years) rates. Color gradient from dark gray to green represents ranges from negative to positive growth: dark gray (-2 to -1), orange (-1 to 0), blue (0 to 1), red (1 to 2), and green (2 to 3). Each map highlights regions with different rates according to this scale.</alt-text>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-12-1616132-g0004.tif"/>
</fig></sec>
<sec>
<title>3.3 The predicted results from 2022 to 2046</title>
<p>The predicted results of the APC model indicated that the number of incidence, prevalence, and DALYs cases for both genders would increase from 2022 to 2046. For males, the number of incidence cases was 4,010,703 in 2021 and was predicted to be 6,801,339 in 2046. The number of prevalence cases was 71,876,664 in 2022 and was projected to reach 139,709,466 in 2046. The number of DALYs was 2,303,952 in 2022 and was expected to be 4,434,962 in 2046. For females, the number of incidence cases would increase from 7,164,166 in 2022 to 10,864,957 in 2046. The number of prevalence cases would increase from 139,256,250 to 237,872,054 during this period. The number of DALYs cases would increase from 4,399,690 to 7,429,105. Moreover, the predicted results showed that the corresponding ASRs would continue to increase over the next 25 years for both genders. In 2021, the ASIR for males was 91.67 per 100,000 population and was predicted to be 109.50 in 2046. The ASPR for males was 1,710.74 in 2022 and was projected to be 2006.14 in 2046. During the same period, the age-standardized DALYs cases increased from 54.62 to 63.98. For females, the ASIR would increase from 156.10 to 166.37, the ASPR would increase from 2,936.99 to 2,977.00, and the ASDAR would increase from 92.86 to 93.83 (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="sec" rid="s11">Supplementary Table 4</xref>).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>The predicted results in the osteoarthritis hand-related numbers and age-standardized rates of incidence, prevalence, and DALYs by sex globally from 2022 to 2046 of the APC model.</p></caption>
<alt-text>Three bar graphs labeled A, B, and C show projections from 2030 to 2045 for females and males, distinguished by colors. Graph A displays incidence numbers and age-standardized rates. Graph B illustrates prevalence numbers and age-standardized rates. Graph C shows Disability-Adjusted Life Years (DALYs) and age-standardized rates. Both female and male data generally increase over time in all graphs.</alt-text>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-12-1616132-g0005.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<sec>
<title>4.1 Summary of key findings</title>
<p>The present study provides a comprehensive analysis of the global burden of HOA in 2021, temporal trends from 1990 to 2021, and projections through 2046, utilizing data from the GBD study. In 2021, HOA was associated with 10.37 million incidence cases, 194.28 million prevalence cases, and 6.17 million DALYs, with ASRs reflecting substantial global and regional disparities. Females exhibited a significantly higher burden across all metrics, with incidence, prevalence, and DALYs counts 1.83, 2.00, and 1.97 times those of males, respectively, aligning with prior epidemiological evidence of sex-specific susceptibility to OA (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). Age distribution patterns showed a peak in incidence cases at advanced ages, followed by a decline, while prevalence and DALYs continued to rise with age, underscoring the chronic and degenerative nature of HOA (<xref ref-type="bibr" rid="B16">16</xref>).</p></sec>
<sec>
<title>4.2 Global and regional disparities</title>
<p>Geographically, middle SDI regions harbored the highest absolute numbers of incidence, prevalence, and DALYs cases, likely driven by large population sizes and increasing aging populations (<xref ref-type="bibr" rid="B17">17</xref>). Conversely, high SDI regions reported the highest age-standardized rates, a finding consistent with studies linking higher socioeconomic status to increased life expectancy and age-related OA prevalence, despite better access to healthcare (<xref ref-type="bibr" rid="B18">18</xref>). Central Asia emerged as a hotspot for HOA, with the highest ASIR (194.58/100,000), ASPR (3,903.67/100,000), and ASDAR (124.56/100,000), possibly influenced by genetic predispositions, occupational risks, or climate-related factors (<xref ref-type="bibr" rid="B19">19</xref>). In contrast, minimal health system regions and sub-Saharan African countries exhibited the lowest rates, which may reflect underdiagnosis, limited healthcare access, or competing disease priorities (<xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>Recent studies suggest that this elevated burden in Central Asia may be underpinned by both genetic and occupational determinants. Polymorphisms in the COL1A1 gene, particularly within the Sp1 binding site, are known to compromise collagen structure and have been associated with increased OA susceptibility. These variants have been reported at higher frequencies in Eastern European and Central Asian populations (<xref ref-type="bibr" rid="B21">21</xref>). Concurrently, epidemiological data from Kazakhstan and Uzbekistan highlight a disproportionately high prevalence of repetitive manual labor in agricultural and textile sectors, with substantial female representation (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). These mechanistic insights provide biological plausibility for the observed regional ASR patterns and underscore the need for integrative surveillance combining genetic, occupational, and demographic risk stratification.</p>
<p>Community-based arthritis interventions have shown promise in low-resource settings. For instance, India&#x00027;s WHO-supported outreach initiatives have achieved symptom relief and functional improvement through ergonomic education and task modification (<xref ref-type="bibr" rid="B24">24</xref>). These scalable, low-cost models offer practical guidance for regions such as Central Asia, where specialized care remains limited. Embedding such strategies within national musculoskeletal health frameworks could strengthen regional responses to the growing HOA burden.</p>
<p>Country-specific analysis highlighted Mongolia, Kazakhstan, and the United States as having high absolute or standardized burdens. The U.S. led in prevalence cases and DALYs, consistent with its aging population and high obesity rates, a known risk factor for OA (<xref ref-type="bibr" rid="B25">25</xref>). Conversely, low-burden regions like Tokelau and Niue likely benefit from smaller populations and potentially healthier lifestyles, though data reliability in microstates warrants caution (<xref ref-type="bibr" rid="B26">26</xref>).</p></sec>
<sec>
<title>4.3 Temporal trends and projections</title>
<p>From 1990 to 2021, global HOA burdens increased in both absolute and age-standardized terms, with ASIR rising by 18.4% and ASPR by 15.1%. These trends mirror the global rise in non-communicable diseases and align with projections for other OA subtypes, such as knee OA, driven by aging populations and changing lifestyles (<xref ref-type="bibr" rid="B27">27</xref>). Cluster analysis revealed divergent regional trends: while low- and middle-income regions (South Asia, sub-Saharan Africa) experienced significant increases, high-income regions like Western Europe and Australasia saw declines, possibly due to improved risk factor management (reduced occupational hazards, better pain management) (<xref ref-type="bibr" rid="B28">28</xref>). Equatorial Guinea&#x00027;s steep increases and Israel&#x00027;s declines highlight the role of socioeconomic development, healthcare infrastructure, and public health interventions in shaping disease trajectories (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>The APC model projections indicate a continued rise in HOA burden through 2046, with female cases expected to outpace male cases due to longer life expectancy and higher baseline prevalence (<xref ref-type="bibr" rid="B16">16</xref>). While age-standardized rates for males are projected to increase by 19.4%, females show a more modest 6.6% rise in ASIR, suggesting potential convergence in sex disparities or evolving risk factors (<xref ref-type="bibr" rid="B30">30</xref>).</p>
<p>The projected narrowing of sex disparities in ASIR may reflect complex demographic and occupational dynamics. As male life expectancy improves globally&#x02014;particularly in middle-income countries&#x02014;the gap in age-related risk exposure between sexes is diminishing (<xref ref-type="bibr" rid="B31">31</xref>). Simultaneously, industrial and informal sectors with high physical demand, such as construction and delivery services, are seeing increased male labor participation, potentially intensifying cumulative hand strain (<xref ref-type="bibr" rid="B32">32</xref>). In contrast, widespread awareness of musculoskeletal health among women, as well as earlier diagnosis and intervention, may temper further ASIR growth. These opposing trends warrant continued monitoring to evaluate whether the projected convergence reflects structural shifts or transitional dynamics.</p>
<p>The observed heterogeneity in HOA burden trends across regions likely reflects differences in public health infrastructure, aging policies, and occupational safety enforcement. In high-income regions such as Western Europe, declining ASRs may be attributable to longstanding investments in musculoskeletal health promotion, early intervention strategies, and ergonomic workplace adaptations (<xref ref-type="bibr" rid="B33">33</xref>). In contrast, rapid increases in South Asia and sub-Saharan Africa may stem from limited access to primary care, low public awareness of joint disorders, and minimal regulatory oversight of occupational hazards (<xref ref-type="bibr" rid="B34">34</xref>). Moreover, the absence of robust national strategies for obesity and chronic disease prevention in many low- and middle-SDI countries has likely contributed to the upward trajectory of HOA burden (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). These findings highlight the importance of integrated, multisectoral policies&#x02014;including weight management programs, aging-friendly workforce initiatives, and improved diagnostic access&#x02014;to mitigate the growing burden of HOA in vulnerable populations (<xref ref-type="bibr" rid="B37">37</xref>).</p></sec>
<sec>
<title>4.4 Comparison with existing literature</title>
<p>Our findings corroborate previous GBD analyses on musculoskeletal disorders, which identify OA as a leading cause of disability worldwide (<xref ref-type="bibr" rid="B38">38</xref>). The marked predominance of HOA burden among women is underpinned by intersecting biological and occupational determinants. Endogenously, estrogen plays a critical role in preserving joint integrity by modulating chondrocyte function, proteoglycan synthesis, and inflammatory pathways. The abrupt decline in estrogen following menopause accelerates articular cartilage degeneration and heightens synovial inflammation, rendering women biologically more susceptible to degenerative joint pathology. Meta-analytical evidence corroborates this association, linking post-menopausal estrogen deficiency with the onset and progression of osteoarthritis in both weight-bearing and non-weight-bearing joints, including the hands (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Although hormone replacement therapy has been proposed as a disease-modifying approach, current evidence remains inconclusive regarding its effectiveness in attenuating HOA progression (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). These pathophysiological mechanisms highlight the fundamental role of hormonal milieu in shaping sex-specific disparities in HOA risk.</p>
<p>Superimposed on this biological vulnerability are occupational exposures that disproportionately affect women. Across many settings, women are overrepresented in informal and underregulated labor sectors&#x02014;such as caregiving, subsistence agriculture, and textile manufacturing&#x02014;that involve repetitive fine motor activity and lack ergonomic safeguards (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>). These cumulative occupational insults, exacerbated by hormonal vulnerability and gendered health-seeking behavior&#x02014;characterized by greater symptom reporting and healthcare utilization among women&#x02014;may increase diagnosis rates (<xref ref-type="bibr" rid="B45">45</xref>). However, these trends are often offset by systemic inequities, including delayed referral pathways and implicit clinical biases that may downplay musculoskeletal complaints in women. Together, these factors point to a multifactorial origin of the sex gap in HOA burden, underscoring the imperative for integrated strategies that address both biological and structural drivers through sex-specific prevention, occupational safeguards, and equitable musculoskeletal care delivery.</p>
<p>The inverse U-shaped distribution of HOA incidence&#x02014;characterized by a peak in middle to late adulthood followed by a subsequent decline&#x02014;stands in contrast to the progressive, age-dependent increase typically observed in knee osteoarthritis (<xref ref-type="bibr" rid="B46">46</xref>). This divergence suggests distinct pathophysiological mechanisms shaped by joint-specific anatomical and functional demands. In the hands, the cumulative impact of fine-motor, repetitive activities performed during working age may drive an earlier onset of joint damage, whereas in weight-bearing joints such as the knee, mechanical load accumulates more linearly with age.</p>
<p>Emerging histological and imaging evidence further supports this divergence (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Articular cartilage in hand joints exhibits lower proteoglycan content, reduced regenerative capacity, and a heightened pro-inflammatory microenvironment compared with the knee. These tissue-level differences may predispose the hands to earlier mechanical fatigue and accelerated degeneration. Moreover, microtrauma resulting from repetitive precision tasks induces periarticular inflammation via distinct biomechanical pathways that differ from the axial loading forces implicated in knee OA pathogenesis. These findings underscore the importance of considering joint-specific exposures and structural characteristics when interpreting epidemiological patterns and designing targeted preventive strategies.</p></sec>
<sec>
<title>4.5 Study limitations</title>
<p>Several limitations should be acknowledged. First, the use of GBD data assumes consistent diagnostic definitions of HOA across regions, which may lead to underreporting in settings with limited clinical capacity. Second, the absence of structural determinants&#x02014;such as income inequality, labor informality, and healthcare access&#x02014;limits interpretation of regional disparities. Third, GBD data lack details on modifiable risks such as occupation or hand trauma, limiting causal inference. Finally, the exclusion of patient-reported outcomes means the lived experience of pain and disability is only partially reflected in DALY estimates.</p></sec></sec>
<sec sec-type="conclusions" id="s5">
<title>5 Conclusion</title>
<p>This study underscores the substantial and growing global burden of HOA, with pronounced sex, age, and regional disparities. The upward trends in both absolute and standardized rates highlight the need for targeted public health strategies, particularly in high-burden regions and aging populations. While challenges in data accuracy and model assumptions exist, the findings provide a robust evidence base for prioritizing HOA in musculoskeletal health agendas, promoting early intervention, and improving healthcare access. Future research should focus on integrating risk factor data and evaluating the effectiveness of preventive measures to mitigate the projected increase in HOA burden.</p></sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s12">Supplementary material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>JW: Writing &#x02013; original draft, Conceptualization. ZS: Writing &#x02013; review &#x00026; editing, Investigation. SP: Software, Writing &#x02013; review &#x00026; editing. ZZ: Data curation, Writing &#x02013; review &#x00026; editing. GuiL: Supervision, Writing &#x02013; review &#x00026; editing. GuaL: Writing &#x02013; review &#x00026; editing. HL: Formal analysis, Writing &#x02013; review &#x00026; editing. GuipL: Writing &#x02013; review &#x00026; editing. RG: Writing &#x02013; review &#x00026; editing, Validation. YL: Writing &#x02013; review &#x00026; editing, Funding acquisition.</p>
</sec>
<ack><title>Acknowledgments</title><p>The authors would like to thank all the professionals who contributed to the discussion and elaboration of this minireview.</p>
</ack>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="correction note" id="s100">
<title>Correction note</title>
<p>This article has been corrected with minor changes. These changes do not impact the scientific content of the article.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declare that no Gen AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2025.1616132/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmed.2025.1616132/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.csv" id="SM1" mimetype="text/csv" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_2.csv" id="SM2" mimetype="text/csv" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_3.csv" id="SM3" mimetype="text/csv" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_4.csv" id="SM4" mimetype="text/csv" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GBD</surname> <given-names>2021 Osteoarthritis Collaborators</given-names></name></person-group>. <article-title>Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021</article-title>. <source>Lancet Rheumatol.</source> (<year>2023</year>) <volume>5</volume>:<fpage>e508</fpage>&#x02013;<lpage>e22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2665-9913(23)00163-7</pub-id><pub-id pub-id-type="pmid">37675071</pub-id></mixed-citation></ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname> <given-names>Q</given-names></name> <name><surname>Chen</surname> <given-names>Q</given-names></name> <name><surname>Jiang</surname> <given-names>T</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>W</given-names></name> <name><surname>Doherty</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Global burden of early-onset osteoarthritis, 1990-2019: results from the Global Burden of Disease Study 2019</article-title>. <source>Ann Rheum Dis.</source> (<year>2024</year>) <volume>83</volume>:<fpage>915</fpage>&#x02013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1136/ard-2023-225324</pub-id><pub-id pub-id-type="pmid">38429104</pub-id></mixed-citation></ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>F</given-names></name> <name><surname>Xu</surname> <given-names>Z</given-names></name> <name><surname>Li</surname> <given-names>XX</given-names></name> <name><surname>Fu</surname> <given-names>ZY</given-names></name> <name><surname>Han</surname> <given-names>RY</given-names></name> <name><surname>Zhang</surname> <given-names>JL</given-names></name> <etal/></person-group>. <article-title>Trends and cross-country inequalities in the global burden of osteoarthritis, 1990-2019: a population-based study</article-title>. <source>Ageing Res Rev.</source> (<year>2024</year>) <volume>99</volume>:<fpage>102382</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2024.102382</pub-id><pub-id pub-id-type="pmid">38917934</pub-id></mixed-citation></ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Z</given-names></name> <name><surname>Xiao</surname> <given-names>Z</given-names></name> <name><surname>Sun</surname> <given-names>C</given-names></name> <name><surname>Xu</surname> <given-names>G</given-names></name> <name><surname>He</surname> <given-names>J</given-names></name></person-group>. <article-title>Global, regional and national burden of osteoarthritis in 1990-2021: a systematic analysis of the global burden of disease study 2021</article-title>. <source>BMC Musculoskelet Disord.</source> (<year>2024</year>) <volume>25</volume>:<fpage>1021</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12891-024-08122-5</pub-id><pub-id pub-id-type="pmid">39702247</pub-id></mixed-citation></ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Guo</surname> <given-names>Y</given-names></name> <name><surname>Chen</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>J</given-names></name></person-group>. <article-title>Osteoarthritis burden and inequality from 1990 to 2021: a systematic analysis for the global burden of disease Study 2021</article-title>. <source>Sci Rep.</source> (<year>2025</year>) <volume>15</volume>:<fpage>8305</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-025-93124-z</pub-id><pub-id pub-id-type="pmid">40065123</pub-id></mixed-citation></ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gignac</surname> <given-names>MAM</given-names></name> <name><surname>Irvin</surname> <given-names>E</given-names></name> <name><surname>Cullen</surname> <given-names>K</given-names></name> <name><surname>Van Eerd</surname> <given-names>D</given-names></name> <name><surname>Beaton</surname> <given-names>DE</given-names></name> <name><surname>Mahood</surname> <given-names>Q</given-names></name> <etal/></person-group>. <article-title>Men and women&#x00027;s occupational activities and the risk of developing osteoarthritis of the knee, hip, or hands: a systematic review and recommendations for future research</article-title>. <source>Arthritis Care Res.</source> (<year>2020</year>) <volume>72</volume>:<fpage>378</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1002/acr.23855</pub-id><pub-id pub-id-type="pmid">30762317</pub-id></mixed-citation></ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collaborators</surname> <given-names>GORF</given-names></name></person-group>. <article-title>Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016</article-title>. <source>Occup Environ Med.</source> (<year>2020</year>) <volume>77</volume>:<fpage>133</fpage>&#x02013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1136/oemed-2019-106008</pub-id><pub-id pub-id-type="pmid">32054817</pub-id></mixed-citation></ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyn</surname> <given-names>R</given-names></name> <name><surname>Heath</surname> <given-names>E</given-names></name> <name><surname>Dubhashi</surname> <given-names>J</given-names></name></person-group>. <article-title>Global implementation of obesity prevention policies: a review of progress, politics, and the path forward</article-title>. <source>Curr Obes Rep.</source> (<year>2019</year>) <volume>8</volume>:<fpage>504</fpage>&#x02013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13679-019-00358-w</pub-id><pub-id pub-id-type="pmid">31673982</pub-id></mixed-citation></ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>CJ</given-names></name> <name><surname>Lopez</surname> <given-names>AD</given-names></name></person-group>. <article-title>Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study</article-title>. <source>Lancet.</source> (<year>1997</year>) <volume>349</volume>:<fpage>1436</fpage>&#x02013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(96)07495-8</pub-id><pub-id pub-id-type="pmid">9164317</pub-id></mixed-citation></ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname> <given-names>T</given-names></name> <name><surname>Flaxman</surname> <given-names>AD</given-names></name> <name><surname>Naghavi</surname> <given-names>M</given-names></name> <name><surname>Lozano</surname> <given-names>R</given-names></name> <name><surname>Michaud</surname> <given-names>C</given-names></name> <name><surname>Ezzati</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title>. <source>Lancet.</source> (<year>2012</year>) <volume>380</volume>:<fpage>2163</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61729-2</pub-id><pub-id pub-id-type="pmid">23245607</pub-id></mixed-citation></ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Han</surname> <given-names>X</given-names></name> <name><surname>Jiang</surname> <given-names>H</given-names></name> <name><surname>Zhang</surname> <given-names>L</given-names></name> <name><surname>Hu</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019</article-title>. <source>Front Public Health.</source> (<year>2022</year>) <volume>10</volume>:<fpage>994619</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2022.994619</pub-id><pub-id pub-id-type="pmid">36159285</pub-id></mixed-citation></ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holford</surname> <given-names>TR</given-names></name></person-group>. <article-title>The estimation of age, period and cohort effects for vital rates</article-title>. <source>Biometrics.</source> (<year>1983</year>) <volume>39</volume>:<fpage>311</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.2307/2531004</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riebler</surname> <given-names>A</given-names></name> <name><surname>Held</surname> <given-names>L</given-names></name></person-group>. <article-title>Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations</article-title>. <source>Biom J.</source> (<year>2017</year>) <volume>59</volume>:<fpage>531</fpage>&#x02013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bimj.201500263</pub-id><pub-id pub-id-type="pmid">28139001</pub-id></mixed-citation></ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname> <given-names>M</given-names></name> <name><surname>Smith</surname> <given-names>E</given-names></name> <name><surname>Hoy</surname> <given-names>D</given-names></name> <name><surname>Nolte</surname> <given-names>S</given-names></name> <name><surname>Ackerman</surname> <given-names>I</given-names></name> <name><surname>Fransen</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study</article-title>. <source>Ann Rheum Dis.</source> (<year>2014</year>) <volume>73</volume>:<fpage>1323</fpage>&#x02013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204763</pub-id><pub-id pub-id-type="pmid">24553908</pub-id></mixed-citation></ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>KD</given-names></name> <name><surname>Thoma</surname> <given-names>LM</given-names></name> <name><surname>Golightly</surname> <given-names>YM</given-names></name></person-group>. <article-title>Epidemiology of osteoarthritis</article-title>. <source>Osteoarthritis Cartilage.</source> (<year>2022</year>) <volume>30</volume>:<fpage>184</fpage>&#x02013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.joca.2021.04.020</pub-id><pub-id pub-id-type="pmid">34534661</pub-id></mixed-citation></ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>DJ</given-names></name> <name><surname>Bierma-Zeinstra</surname> <given-names>S</given-names></name></person-group>. <article-title>Osteoarthritis</article-title>. <source>Lancet.</source> (<year>2019</year>) <volume>393</volume>:<fpage>1745</fpage>&#x02013;<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(19)30417-9</pub-id><pub-id pub-id-type="pmid">31034380</pub-id></mixed-citation></ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2019 Diseases and Injuries Collaborators</collab></person-group>. <article-title>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>396</volume>:<fpage>1204</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30925-9</pub-id><pub-id pub-id-type="pmid">33069326</pub-id></mixed-citation></ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Jordan</surname> <given-names>JM</given-names></name></person-group>. <article-title>Epidemiology of osteoarthritis</article-title>. <source>Clin Geriatr Med.</source> (<year>2010</year>) <volume>26</volume>:<fpage>355</fpage>&#x02013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cger.2010.03.001</pub-id><pub-id pub-id-type="pmid">20699159</pub-id></mixed-citation></ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litwic</surname> <given-names>A</given-names></name> <name><surname>Edwards</surname> <given-names>MH</given-names></name> <name><surname>Dennison</surname> <given-names>EM</given-names></name> <name><surname>Cooper</surname> <given-names>C</given-names></name></person-group>. <article-title>Epidemiology and burden of osteoarthritis</article-title>. <source>Br Med Bull.</source> (<year>2013</year>) <volume>105</volume>:<fpage>185</fpage>&#x02013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bmb/lds038</pub-id><pub-id pub-id-type="pmid">23337796</pub-id></mixed-citation></ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>D</given-names></name> <name><surname>Wong</surname> <given-names>P</given-names></name> <name><surname>Guo</surname> <given-names>C</given-names></name> <name><surname>Tam</surname> <given-names>LS</given-names></name> <name><surname>Gu</surname> <given-names>J</given-names></name></person-group>. <article-title>Pattern and trend of five major musculoskeletal disorders in China from 1990 to 2017: findings from the Global Burden of Disease Study 2017</article-title>. <source>BMC Med</source>. (<year>2021</year>) <volume>19</volume>:<fpage>34</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-021-01905-w</pub-id><pub-id pub-id-type="pmid">33536019</pub-id></mixed-citation></ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>B</given-names></name> <name><surname>Huang</surname> <given-names>D</given-names></name> <name><surname>Ma</surname> <given-names>K</given-names></name> <name><surname>Deng</surname> <given-names>X</given-names></name> <name><surname>Shi</surname> <given-names>D</given-names></name> <name><surname>Wu</surname> <given-names>F</given-names></name> <etal/></person-group>. <article-title>Association of COL1A1 rs1800012 polymorphism with musculoskeletal degenerative diseases: a meta-analysis</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<fpage>75488</fpage>&#x02013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.20797</pub-id><pub-id pub-id-type="pmid">29088884</pub-id></mixed-citation></ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavana</surname></name> <name><surname>Smrithi</surname> <given-names>A</given-names></name> <name><surname>Pruthviraj</surname> <given-names>R</given-names></name></person-group>. <article-title>Prevalence of musculoskeletal disorders among self-employed female tailors in selected places of Bengaluru</article-title>. <source>Indian J Physiother Occup Ther</source>. (<year>2023</year>). doi: <pub-id pub-id-type="doi">10.37506/ijpot.v17i2.19232</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandy</surname> <given-names>R</given-names></name></person-group>. <article-title>Prevalence of upper limb disorders among female librarians</article-title>. <source>Occup Med.</source> (<year>2013</year>) <volume>63</volume>:<fpage>432</fpage>&#x02013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1093/occmed/kqt080</pub-id><pub-id pub-id-type="pmid">23859850</pub-id></mixed-citation></ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname> <given-names>VL</given-names></name> <name><surname>Chopra</surname> <given-names>A</given-names></name></person-group>. <article-title>Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan model</article-title>. <source>J Rheumatol</source>. (<year>2009</year>) <volume>36</volume>:<fpage>61422</fpage>. doi: <pub-id pub-id-type="doi">10.3899/jrheum.080675</pub-id><pub-id pub-id-type="pmid">19208598</pub-id></mixed-citation></ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbour</surname> <given-names>KE</given-names></name> <name><surname>Helmick</surname> <given-names>CG</given-names></name> <name><surname>Boring</surname> <given-names>M</given-names></name> <name><surname>Brady</surname> <given-names>TJ</given-names></name></person-group>. <article-title>Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013-2015</article-title>. <source>Morb Mortal Wkly Rep.</source> (<year>2017</year>) <volume>66</volume>:<fpage>246</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.15585/mmwr.mm6609e1</pub-id><pub-id pub-id-type="pmid">28278145</pub-id></mixed-citation></ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators</collab></person-group>. <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>392</volume>:<fpage>1789</fpage>&#x02013;<lpage>858</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmid">30496104</pub-id></mixed-citation></ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoy</surname> <given-names>D</given-names></name> <name><surname>Bain</surname> <given-names>C</given-names></name> <name><surname>Williams</surname> <given-names>G</given-names></name> <name><surname>March</surname> <given-names>L</given-names></name> <name><surname>Brooks</surname> <given-names>P</given-names></name> <name><surname>Blyth</surname> <given-names>F</given-names></name> <etal/></person-group>. <article-title>A systematic review of the global prevalence of low back pain</article-title>. <source>Arthritis Rheum.</source> (<year>2012</year>) <volume>64</volume>:<fpage>2028</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1002/art.34347</pub-id><pub-id pub-id-type="pmid">22231424</pub-id></mixed-citation></ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanifer</surname> <given-names>JW</given-names></name> <name><surname>Jing</surname> <given-names>B</given-names></name> <name><surname>Tolan</surname> <given-names>S</given-names></name> <name><surname>Helmke</surname> <given-names>N</given-names></name> <name><surname>Mukerjee</surname> <given-names>R</given-names></name> <name><surname>Naicker</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis</article-title>. <source>Lancet Glob Health.</source> (<year>2014</year>) <volume>2</volume>:<fpage>e174</fpage>&#x02013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2214-109X(14)70002-6</pub-id><pub-id pub-id-type="pmid">25102850</pub-id></mixed-citation></ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name> <name><surname>Ye</surname> <given-names>Y</given-names></name></person-group>. <article-title>Trends and projections of the burden of osteoarthritis disease in China and globally: a comparative study of the 2019 global burden of disease database</article-title>. <source>Prev Med Rep.</source> (<year>2024</year>) <volume>37</volume>:<fpage>102562</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pmedr.2023.102562</pub-id><pub-id pub-id-type="pmid">38205169</pub-id></mixed-citation></ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeser</surname> <given-names>RF</given-names></name> <name><surname>Goldring</surname> <given-names>SR</given-names></name> <name><surname>Scanzello</surname> <given-names>CR</given-names></name> <name><surname>Goldring</surname> <given-names>MB</given-names></name></person-group>. <article-title>Osteoarthritis: a disease of the joint as an organ</article-title>. <source>Arthritis Rheum.</source> (<year>2012</year>) <volume>64</volume>:<fpage>1697</fpage>&#x02013;<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1002/art.34453</pub-id><pub-id pub-id-type="pmid">22392533</pub-id></mixed-citation></ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GBD</surname> <given-names>2021 Global AMD Collaborators</given-names></name></person-group>. <article-title>Global burden of vision impairment due to age-related macular degeneration, 1990-2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study (2021)</article-title>. <source>Lancet Glob Health</source>. (<year>2025</year>) <volume>13</volume>:<fpage>e117590</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S2214-109X(25)00143-3</pub-id><pub-id pub-id-type="pmid">40580986</pub-id></mixed-citation></ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GBD</surname> <given-names>2021 Gout Collaborators</given-names></name></person-group>. <article-title>Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021</article-title>. <source>Lancet Rheumatol.</source> (<year>2024</year>) <volume>6</volume>:<fpage>e50717</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S2665-9913(24)00117-6</pub-id><pub-id pub-id-type="pmid">38996590</pub-id></mixed-citation></ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname> <given-names>AM</given-names></name> <name><surname>Woolf</surname> <given-names>AD</given-names></name> <name><surname>Dreinh&#x000F6;fer</surname> <given-names>K</given-names></name> <name><surname>Homb</surname> <given-names>N</given-names></name> <name><surname>Hoy</surname> <given-names>DG</given-names></name> <name><surname>Kopansky-Giles</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Reducing the global burden of musculoskeletal conditions</article-title>. <source>Bull World Health Organ.</source> (<year>2018</year>) <volume>96</volume>:<fpage>366</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.2471/BLT.17.204891</pub-id><pub-id pub-id-type="pmid">29875522</pub-id></mixed-citation></ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieza</surname> <given-names>A</given-names></name> <name><surname>Causey</surname> <given-names>K</given-names></name> <name><surname>Kamenov</surname> <given-names>K</given-names></name> <name><surname>Hanson</surname> <given-names>SW</given-names></name> <name><surname>Chatterji</surname> <given-names>S</given-names></name> <name><surname>Vos</surname> <given-names>T</given-names></name></person-group>. <article-title>Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>396</volume>:<fpage>2006</fpage>&#x02013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32340-0</pub-id><pub-id pub-id-type="pmid">33275908</pub-id></mixed-citation></ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>NCD Risk Factor Collaboration (NCD-RisC)</collab></person-group>. <article-title>Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 12879 million children, adolescents, and adults</article-title>. <source>Lancet</source>. (<year>2017</year>) <volume>390</volume>:<fpage>2627</fpage>&#x02013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32129-3</pub-id><pub-id pub-id-type="pmid">29029897</pub-id></mixed-citation></ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Global Burden of Disease Study 2013 Collaborators</collab></person-group>. <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>. <source>Lancet</source>. (<year>2015</year>) <volume>386</volume>:<fpage>743800</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60692-4</pub-id><pub-id pub-id-type="pmid">26063472</pub-id></mixed-citation></ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname> <given-names>M</given-names></name> <name><surname>Gluckman</surname> <given-names>P</given-names></name> <name><surname>Nutbeam</surname> <given-names>D</given-names></name> <name><surname>Hearn</surname> <given-names>J</given-names></name></person-group>. <article-title>Priority actions for the non-communicable disease crisis</article-title>. <source>Lancet.</source> (<year>2011</year>) <volume>377</volume>:<fpage>1438</fpage>&#x02013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60393-0</pub-id><pub-id pub-id-type="pmid">21474174</pub-id></mixed-citation></ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>S</given-names></name> <name><surname>Wang</surname> <given-names>B</given-names></name> <name><surname>Fan</surname> <given-names>S</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Zhan</surname> <given-names>Y</given-names></name> <name><surname>Ye</surname> <given-names>D</given-names></name></person-group>. <article-title>Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study</article-title>. <source>BMJ Open.</source> (<year>2022</year>) <volume>12</volume>:<fpage>e062183</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2022-062183</pub-id><pub-id pub-id-type="pmid">35768100</pub-id></mixed-citation></ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>F</given-names></name> <name><surname>Xing</surname> <given-names>X</given-names></name> <name><surname>Jin</surname> <given-names>Q</given-names></name> <name><surname>Wang</surname> <given-names>XM</given-names></name> <name><surname>Dai</surname> <given-names>P</given-names></name> <name><surname>Han</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Sex differences orchestrated by androgens at single-cell resolution</article-title>. <source>Nature.</source> (<year>2024</year>) <volume>629</volume>:<fpage>193</fpage>&#x02013;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-024-07291-6</pub-id><pub-id pub-id-type="pmid">38600383</pub-id></mixed-citation></ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derwich</surname> <given-names>M</given-names></name> <name><surname>Mitus-Kenig</surname> <given-names>M</given-names></name> <name><surname>Pawlowska</surname> <given-names>E</given-names></name></person-group>. <article-title>Mechanisms of action and efficacy of hyaluronic acid, corticosteroids and platelet-rich plasma in the treatment of temporomandibular joint osteoarthritis-a systematic review</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>7405</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22147405</pub-id><pub-id pub-id-type="pmid">34299024</pub-id></mixed-citation></ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulati</surname> <given-names>M</given-names></name> <name><surname>Dursun</surname> <given-names>E</given-names></name> <name><surname>Vincent</surname> <given-names>K</given-names></name> <name><surname>Watt</surname> <given-names>FE</given-names></name></person-group>. <article-title>The influence of sex hormones on musculoskeletal pain and osteoarthritis</article-title>. <source>Lancet Rheumatol.</source> (<year>2023</year>) <volume>5</volume>:<fpage>e22538</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S2665-9913(23)00060-7</pub-id><pub-id pub-id-type="pmid">38251525</pub-id></mixed-citation></ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spector</surname> <given-names>TD</given-names></name> <name><surname>Nandra</surname> <given-names>D</given-names></name> <name><surname>Hart</surname> <given-names>DJ</given-names></name> <name><surname>Doyle</surname> <given-names>DV</given-names></name></person-group>. <article-title>Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford Study</article-title>. <source>Ann Rheum Dis</source>. (<year>1997</year>) <volume>56</volume>:<fpage>4324</fpage>. doi: <pub-id pub-id-type="doi">10.1136/ard.56.7.432</pub-id><pub-id pub-id-type="pmid">9486006</pub-id></mixed-citation></ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname> <given-names>WY</given-names></name> <name><surname>Vliet Vlieland</surname> <given-names>TPM</given-names></name> <name><surname>Rosendaal</surname> <given-names>FR</given-names></name> <name><surname>Huizinga</surname> <given-names>TWJ</given-names></name> <name><surname>Kloppenburg</surname> <given-names>M</given-names></name></person-group>. <article-title>Risk factors for hand osteoarthritis: a systematic review</article-title>. <source>Ann Rheum Dis.</source> (<year>2011</year>) <volume>70</volume>:<fpage>124</fpage>&#x02013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1136/ard.2010.133603</pub-id><pub-id pub-id-type="pmid">21081529</pub-id></mixed-citation></ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugen</surname> <given-names>IK</given-names></name> <name><surname>Englund</surname> <given-names>M</given-names></name> <name><surname>Aliabadi</surname> <given-names>P</given-names></name> <name><surname>Niu</surname> <given-names>J</given-names></name> <name><surname>Clancy</surname> <given-names>M</given-names></name> <name><surname>Felson</surname> <given-names>DT</given-names></name></person-group>. <article-title>Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study</article-title>. <source>Ann Rheum Dis.</source> (<year>2011</year>) <volume>70</volume>:<fpage>1581</fpage>&#x02013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1136/ard.2011.150078</pub-id><pub-id pub-id-type="pmid">21622766</pub-id></mixed-citation></ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldron</surname> <given-names>HA</given-names></name></person-group>. <article-title>Prevalence and distribution of osteoarthritis in a population from Georgian and early Victorian London</article-title>. <source>Ann. Rheum Dis</source>. (<year>1991</year>) <volume>50</volume>:<fpage>3017</fpage>. doi: <pub-id pub-id-type="doi">10.1136/ard.50.5.301</pub-id><pub-id pub-id-type="pmid">2042984</pub-id></mixed-citation></ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname> <given-names>SL</given-names></name> <name><surname>Johnston</surname> <given-names>RV</given-names></name> <name><surname>McDonald</surname> <given-names>S</given-names></name> <name><surname>Worthley</surname> <given-names>D</given-names></name> <name><surname>Campbell</surname> <given-names>TM</given-names></name> <name><surname>Cyril</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Stem cell injections for osteoarthritis of the knee</article-title>. <source>Cochrane Database Syst Rev.</source> (<year>2025</year>) <volume>4</volume>:<fpage>CD013342</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD013342.pub2</pub-id><pub-id pub-id-type="pmid">40169165</pub-id></mixed-citation></ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guermazi</surname> <given-names>A</given-names></name> <name><surname>Roemer</surname> <given-names>FW</given-names></name> <name><surname>Hayashi</surname> <given-names>D</given-names></name></person-group>. <article-title>Imaging of osteoarthritis: update from a radiological perspective</article-title>. <source>Curr Opin Rheumatol.</source> (<year>2011</year>) <volume>23</volume>:<fpage>48491</fpage>. doi: <pub-id pub-id-type="doi">10.1097/BOR.0b013e328349c2d2</pub-id><pub-id pub-id-type="pmid">21760511</pub-id></mixed-citation></ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boesen</surname> <given-names>M</given-names></name> <name><surname>Ellegaard</surname> <given-names>K</given-names></name> <name><surname>Henriksen</surname> <given-names>M</given-names></name> <name><surname>Gudbergsen</surname> <given-names>H</given-names></name> <name><surname>Hansen</surname> <given-names>P</given-names></name> <name><surname>Bliddal</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Osteoarthritis year in review 2016: imaging</article-title>. <source>Osteoarthr Cartilage.</source> (<year>2017</year>) <volume>25</volume>:<fpage>21626</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.joca.2016.12.009</pub-id><pub-id pub-id-type="pmid">27965137</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2044610/overview">Lichun Qiao</ext-link>, Xi&#x00027;an Jiaotong University, China</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1460815/overview">Xiaoyuan Qian</ext-link>, Xiangyang Central Hospital, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2912815/overview">JingXuan Zhou</ext-link>, Peking University, China</p>
</fn>
</fn-group>
</back>
</article>